Instalab
logoInstalab

Total Primary Bile Acids

Stool Test
An emerging research-stage marker that may offer a window into how your liver and gut microbes work together, beyond what standard liver enzymes show.
4.9 (4,673 reviews)
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Collect your sample
At home
Get results
Explained with clear next steps, no medical jargon

Should you take a Total Primary Bile Acids test?

This test is most useful if any of these apply to you.

Living with Fatty Liver Disease
Bile acid patterns shift with fatty liver severity, offering a non-imaging window into how your liver and gut are coping over time.
Working on Gut Health
Your microbiome converts primary bile acids into secondary ones, and the balance reflects how well that conversion is happening day to day.
Dealing with Chronic Digestive Issues
If diarrhea, bloating, or fat malabsorption symptoms are unexplained, bile acid patterns can point toward a real underlying mechanism.
Watching Your Heart and Liver Together
Low primary bile acids have been linked to heart disease and high levels to liver disease, so the trend offers an early read on either direction.

About Total Primary Bile Acids

Your liver builds the original bile acids that digest the fat in every meal, and those molecules cycle between your gut and your bloodstream many times a day. The two your liver makes directly from cholesterol, called primary bile acids, are cholic acid (CA) and chenodeoxycholic acid (CDCA). Most get absorbed and recycled, but the fraction that escapes into stool tells a story about your liver, your gut transit, and the bacteria living there.

Measuring total primary bile acids in stool is different from measuring them in blood. It captures what survived the trip through your gut without being chemically modified by microbes, which makes the number sensitive to liver output and microbiome activity at the same time. Most published research has used blood-based measurements, so applying those findings to a stool reading takes some interpretation.

What This Test Actually Captures

The test sums cholic acid and chenodeoxycholic acid along with their glycine-attached and taurine-attached forms (sometimes abbreviated GCA, TCA, GCDCA, and TCDCA). These are the bile acids your liver assembles from cholesterol before gut bacteria get a chance to convert them into secondary bile acids like deoxycholic acid and lithocholic acid. A high primary bile acid level in stool can mean your liver is producing more, your gut is moving them through quickly, or your microbes are not converting them efficiently.

Why Bile Acids Matter Beyond Digestion

Bile acids do more than emulsify dietary fat. They activate cellular receptors that help regulate blood sugar, cholesterol metabolism, inflammation, and immune signaling. When the liver-to-gut bile acid loop drifts off pattern, the downstream signals can shift across multiple body systems, which is why bile acid profiles are studied in liver disease, metabolic disease, heart disease, and even some cancers.

Fatty Liver Disease

In adults with non-alcoholic fatty liver disease (a buildup of fat in the liver not caused by drinking), fecal unconjugated primary bile acids and total fecal bile acids run higher than in healthy controls. A meta-analysis of metabolic dysfunction-associated steatotic liver disease (MASLD, the newer name for fatty liver tied to metabolic problems) also found that total primary bile acids, both conjugated and unconjugated, sit higher than in healthy comparison groups.

The pattern gets more pronounced with disease severity. In people with biopsy-confirmed non-alcoholic steatohepatitis (NASH, the inflamed and damaging form of fatty liver), circulating primary bile acids and conjugated forms rise alongside worsening features like inflammation, ballooned liver cells, and fibrosis. The shift is not random; it tracks with histology, suggesting bile acids reflect what the liver is actually doing under the surface.

Cholestatic Liver Conditions

In primary sclerosing cholangitis (PSC, an autoimmune scarring of the bile ducts), people show distinctive primary bile acid patterns and a higher ratio of primary to secondary bile acids in plasma compared to controls. A bile acid composite score in PSC predicted five-year hepatic decompensation better than standard liver labs in a study of 810 patients. Bile duct sampling has also revealed that PSC produces primary bile acid signatures different from other cholestatic diseases.

Liver Cancer Risk

In two prospective Asian cohorts, people who later developed hepatocellular carcinoma (liver cancer arising from liver cells) had higher pre-diagnostic total primary bile acids in serum than matched controls. Each doubling of the taurine-to-glycine conjugation ratio for primary bile acids was tied to roughly 34 to 48 percent higher liver cancer risk. The secondary-to-primary bile acid ratio ran lower in cases.

These were blood measurements, not stool, so they should be read as indirect evidence about what stool primary bile acids might mean. The signal is strongest in chronic hepatitis B carriers and in people with NASH that has progressed to cancer, where bile acid patterns appear shifted years before any tumor shows up.

Heart and Metabolic Disease

Lower, not higher, primary bile acids are concerning here. In a study of 162 chronic heart failure patients, plasma primary bile acid levels ran lower and the ratio of secondary to primary bile acids was elevated, with the pattern tied to worse survival in unadjusted analysis. In people undergoing coronary angiography, lower total bile acids independently predicted coronary artery disease (heart artery blockages), suggesting that a depleted primary bile acid pool may itself signal cardiovascular trouble.

Diabetes risk goes in two directions depending on which form of the bile acid you measure. In nearly 55,000 initially normal-blood-sugar Chinese adults, higher unconjugated cholic acid and chenodeoxycholic acid were tied to lower future risk of type 2 diabetes, while their conjugated forms were tied to higher risk. Prediabetes and type 2 diabetes show altered bile acid patterns, but obesity alone does not.

Why the Same Number Can Mean Different Things

Total primary bile acids is a pattern indicator, not a simple high-equals-bad lab value. In fatty liver, gallstones, and certain liver cancers, the level runs high. In chronic heart failure and coronary disease, it runs low. The unifying idea is that this number reflects the balance of liver output, gut transit, and microbial activity. Both ends of the spectrum can be a problem because both ends signal a liver-gut system that is not in its usual rhythm. The clinical meaning depends on what other markers are doing alongside it.

Gallstone Disease

A meta-analysis of gallstone disease found that serum total bile acids and the conjugated primary bile acids (GCA, TCA, GCDCA, TCDCA) sit higher in people with stones, and the authors propose them as candidates for early identification. The pattern reinforces the idea that primary bile acids reflect upstream pressure on the bile system before stones form.

Reference Ranges

Stool primary bile acid testing is a research-stage marker. There are no professional society cutpoints for what is normal, optimal, or elevated when measured in stool. Most published values come from research cohorts using mass spectrometry methods that vary across labs, and units (often nanograms per gram of stool, a way of expressing tiny amounts in a standard sample size) differ between studies. What this means in practice: do not chase a specific target number. Instead, treat your first reading as a personal baseline and watch how it moves with time and intervention.

Because the test is run on different platforms with different reference populations, comparing your number across two different labs can be misleading. The most useful comparisons are within the same lab, on the same assay, with the same collection conditions.

Tracking Your Trend

A single stool bile acid reading is a snapshot of one bowel movement. Bile acid output varies with what you ate, how quickly your gut emptied, what your microbiome was doing that week, and where you are in the day. The number tells you much more when you have two or three readings spaced months apart, especially around a deliberate change like a new diet, a new medication, or a microbiome-focused intervention.

A reasonable cadence: get a baseline, retest in three to six months if you are making changes that should affect liver or gut biology, and then at least annually to watch the trajectory. If your first result is unexpected, repeat it before drawing conclusions. Day-to-day variability in stool bile acids is large enough that a single high or low reading is not a diagnosis.

When Results Can Be Misleading

  • Recent antibiotics: a course of antibiotics can wipe out the gut bacteria that convert primary bile acids to secondary forms, temporarily inflating the primary bile acid number without any change in your underlying biology.
  • Bile acid sequestrant medications: drugs like cholestyramine bind bile acids in the gut and dramatically alter what shows up in stool. The reading reflects the drug, not your native bile acid biology.
  • Ursodeoxycholic acid (UDCA, a synthetic bile acid used for cholestatic liver conditions): this medication shifts bile acid composition in plasma and bile, including lowering cholic acid and chenodeoxycholic acid concentrations, which can make a primary bile acid measurement look artificially low.
  • Diet and fasting state in the days before collection: bile acid levels are higher in non-fasted than fasted samples, and a fatty meal the night before changes what reaches the colon.

What to Do With an Abnormal Result

An isolated high or low stool primary bile acid is not a diagnosis. The next step depends on the pattern around it and your symptoms. If your reading is high and you have known fatty liver risk factors (overweight, prediabetes, elevated triglycerides), pair this with a liver enzyme panel (ALT, AST, GGT), a lipid panel, and consider liver imaging. If your reading is low and you have known heart disease or risk factors, the bile acid finding is informational rather than actionable, but it fits a pattern worth raising with a cardiologist.

If your stool bile acid pattern is unusual and you have chronic digestive symptoms, an evaluation by a gastroenterologist focused on bile acid malabsorption, microbiome health, and liver function is reasonable. A hepatologist becomes relevant if liver enzymes are also abnormal or imaging suggests liver fibrosis. The point of this number is not to act on it in isolation but to use it as one signal in a larger workup.

What Moves This Biomarker

Evidence-backed interventions that affect your Total Primary Bile Acids level

Up & Down
Cholestyramine (bile acid sequestrant)
Cholestyramine binds bile acids in the gut and changes how they appear in stool. In a study of 33 people with primary biliary cholangitis (an autoimmune liver condition), cholestyramine altered fecal bile acid profiles substantially. The effect on the stool number reflects the drug binding bile acids rather than a change in your underlying liver biology, so a stool primary bile acid reading taken while on this medication should not be interpreted as a measure of native bile acid metabolism.
MedicationStrong Evidence
Decrease
Aldafermin (an experimental FGF19 hormone analogue)
Aldafermin substantially suppresses hydrophobic and glycine-conjugated primary bile acids (especially GCA and GCDCA) in people with NASH and primary sclerosing cholangitis. In pooled analysis across trials of patients with metabolic and cholestatic liver diseases, the reductions correlated with lower levels of a fibrosis blood marker called Pro-C3. These were serum and plasma measurements rather than stool, so the effect on stool primary bile acids has not been directly confirmed but is biologically expected.
MedicationStrong Evidence
Increase
Bariatric surgery (gastric bypass or duodenal switch)
In a randomized trial of 60 adults followed for five years after gastric bypass or duodenal switch, total bile acids and primary bile acids in serum increased substantially over time, with greater increases after duodenal switch. These are serum measurements rather than stool, so the effect on stool primary bile acids has not been directly tested. The shift reflects a fundamental rewiring of how bile circulates after surgery.
LifestyleStrong Evidence
Decrease
Ursodeoxycholic acid (UDCA, a synthetic bile acid used in cholestatic liver disease)
UDCA increases total plasma bile acids overall but specifically lowers cholic acid and chenodeoxycholic acid concentrations, which are the two primary bile acids the stool test sums. This was measured in plasma and bile in primary biliary cholangitis, not in stool, so the effect on stool primary bile acids is indirect. If you are on UDCA, your primary bile acid number is being shaped by the medication and should be interpreted in that context.
MedicationModerate Evidence
Decrease
Maralixibat (an ileal bile acid transporter inhibitor)
Maralixibat blocks reabsorption of bile acids in the gut. In a pilot study of 27 adults with primary sclerosing cholangitis, it lowered serum bile acids. Because the drug forces more bile acids out into stool, stool primary bile acids would be expected to rise on this treatment, but the direct effect on the stool measurement has not been quantified.
MedicationModerate Evidence
Decrease
Glycodeoxycholic acid (GDCA) supplementation
Oral glycodeoxycholic acid raised the gut hormone FGF19 and suppressed primary bile acid synthesis (lower cholic acid and chenodeoxycholic acid in serum and lower C4, a marker of bile acid synthesis) in a study of healthy men. The metabolic benefits were minimal, and some participants developed liver enzyme changes and digestive side effects. This was a serum-based study, so the effect on stool primary bile acids is indirect.
SupplementModerate Evidence

Frequently Asked Questions

Panels containing Total Primary Bile Acids

Total Primary Bile Acids is included in these pre-built panels.

References

21 studies
  1. Mouzaki M, Wang a, Bandsma R, Comelli E, Arendt B, Zhang L, Fung S, Fischer S, Mcgilvray I, Allard JPLoS ONE2016
  2. Puri P, Daita K, Joyce AR, Mirshahi F, Santhekadur P, Cazanave S, Luketic V, Siddiqui M, Boyett SL, Min H, Kumar DP, Kohli R, Zhou H, Hylemon P, Contos M, Idowu M, Sanyal aHepatology2018
  3. Mousa O, Juran B, Mccauley BM, Vesterhus M, Folseraas T, Turgeon CT, Ali a, Schlicht E, Atkinson E, Hu C, Harnois D, Carey E, Gossard a, Oglesbee D, Eaton J, Larusso N, Gores G, Karlsen T, Lazaridis KHepatology2020
  4. Kayashima a, Sujino T, Fukuhara S, Miyamoto K, Kubosawa Y, Ichikawa M, Kawasaki S, Takabayashi K, Iwasaki E, Kato M, Honda a, Kanai T, Nakamoto NHepatology Communications2024